# Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

> **NCT00550537** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 116 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** carboplatin
- **DRUG:** erlotinib hydrochloride
- **DRUG:** paclitaxel
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **GENETIC:** proteomic profiling
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00550537
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-09
- **Final completion:** 2013-12
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550537, "Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00550537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*